Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

Cells. 2021 Jan 5;10(1):71. doi: 10.3390/cells10010071.

Abstract

The global obesity epidemic continues to rise worldwide. In this context, unraveling new interconnections between biological systems involved in obesity etiology is highly relevant. Dysregulation of the endocannabinoidome (eCBome) is associated with metabolic complications in obesity. This study aims at deciphering new associations between circulating endogenous bioactive lipids belonging to the eCBome and metabolic parameters in a population of overweight or obese individuals with metabolic syndrome. To this aim, we combined different multivariate exploratory analysis methods: canonical correlation analysis and principal component analysis, revealed associations between eCBome subsets, and metabolic parameters such as leptin, lipopolysaccharide-binding protein, and non-esterified fatty acids (NEFA). Subsequent construction of predictive regression models according to the linear combination of selected endocannabinoids demonstrates good prediction performance for NEFA. Descriptive approaches reveal the importance of specific circulating endocannabinoids and key related congeners to explain variance in the metabolic parameters in our cohort. Analysis of quartiles confirmed that these bioactive lipids were significantly higher in individuals characterized by important levels for aforementioned metabolic variables. In conclusion, by proposing a methodology for the exploration of large-scale data, our study offers additional evidence of the existence of an interplay between eCBome related-entities and metabolic parameters known to be altered in obesity.

Trial registration: ClinicalTrials.gov NCT02637115.

Keywords: LBP; NEFA; endocannabinoidome; endocannabinoids; human; leptin; metabolic syndrome; multivariate analysis; obesity.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Proteins
  • Adult
  • Carrier Proteins / blood*
  • Endocannabinoids / blood*
  • Fatty Acids / blood*
  • Female
  • Humans
  • Insulin Resistance*
  • Leptin / blood*
  • Male
  • Membrane Glycoproteins / blood*
  • Obesity / blood*

Substances

  • Acute-Phase Proteins
  • Carrier Proteins
  • Endocannabinoids
  • Fatty Acids
  • LEP protein, human
  • Leptin
  • Membrane Glycoproteins
  • lipopolysaccharide-binding protein

Associated data

  • ClinicalTrials.gov/NCT02637115